Frontiers in Immunology (Jan 2025)

Cholesterol metabolism regulator SREBP2 inhibits HBV replication via suppression of HBx nuclear translocation

  • Fan Yang,
  • Fan Yang,
  • Feng Hu,
  • Hongxiao Song,
  • Tie Li,
  • Fengchao Xu,
  • Jing Xu,
  • Le Wang,
  • Fei Wang,
  • Yujia Zhu,
  • Mian Huang,
  • Yanli Gao,
  • Min Rao,
  • Haichun Ma,
  • Guangyun Tan

DOI
https://doi.org/10.3389/fimmu.2024.1519639
Journal volume & issue
Vol. 15

Abstract

Read online

The intricate link between cholesterol metabolism and host immune responses is well recognized, but the specific mechanisms by which cholesterol biosynthesis influences hepatitis B virus (HBV) replication remain unclear. In this study, we show that SREBP2, a key regulator of cholesterol metabolism, inhibits HBV replication by interacting directly with the HBx protein, thereby preventing its nuclear translocation. We also found that inhibiting the ER-to-Golgi transport of the SCAP-SREBP2 complex or blocking SREBP2 maturation significantly enhances HBV suppression. Notably, we demonstrate that the C-terminal domain (CTD) of SREBP2, rather than its N-terminal domain (NTD), mediates this inhibition by interacting with HBx and promoting its extracellular secretion, thus reducing nuclear HBx accumulation. These findings reveal a novel regulatory pathway that links cholesterol metabolism to HBV replication via SREBP2-mediated control of HBx localization. This insight provides a potential basis for new therapeutic strategies against HBV infection, addressing an important global health issue.

Keywords